Latest news
Zentalis Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $7.44, Implies 49% Upside - TradingViewTradingView · Fri, 07 Aug 2026 17:20:35 GMTZentalis Q2 net loss widens on higher R&D costs - TradingViewTradingView · Thu, 06 Aug 2026 21:36:04 GMTZentalis Pharmaceuticals, Inc. 2Q 2026: Net loss $(42.3M), EPS $(0.59) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 20:36:00 GMTZNTL: Q2 2026 net loss widened to $42.3M as R&D spending rose for late-stage azenosertib trials - TradingViewTradingView · Thu, 06 Aug 2026 20:18:19 GMTZNTL: Clinical and regulatory progress advances, with $174.6M cash runway into late 2027 despite higher losses - TradingViewTradingView · Thu, 06 Aug 2026 09:02:20 GMTZNTL Q2'26 Earnings: revenue estimate is 0 USD - TradingViewTradingView · Wed, 05 Aug 2026 11:00:15 GMT